Sort   by:  
 Page size 
UnknownCheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Not available
S-EPMC6161834 | biostudies-literature
TranscriptomicsA molecular signature for MET-targeted therapy
Constitutive MET signaling promotes invasiveness in primary and recurrent GBM; however, current MET-targeting strategies lack of effective biomarkers for selecting suitable patients for treatment. Here, we identified a predictive signature potentially valuable for indicating vulnerability to MET-tar...
ORGANISM(S): Mus musculus 
2016-01-05 | E-GEOD-64667 | biostudies-arrayexpress
TranscriptomicsCD34+DNAMbrightCXCR4+ CLP mobilized in chronic inflammation
During the course of many chronic inflammatory disorders, a persistent Natural Killer (NK) cell derangement and activation is observed. While increased cell turnover is expected in these cases, little is known about whether and how NK cell homeostatic balance and numbers are maintained by CD34+ prog...
ORGANISM(S): Homo sapiens 
2015-07-01 | E-GEOD-69557 | biostudies-arrayexpress
UnknownRapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
Not available
S-EPMC7466335 | biostudies-literature
UnknownAdjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
Not available
S-EPMC12914490 | biostudies-literature
UnknownRan signaling in melanoma: implications for the development of alternative therapeutic strategies.
Not available
S-EPMC4277926 | biostudies-literature
UnknownClinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational Study.
Not available
S-EPMC12153653 | biostudies-literature
TranscriptomicsPermissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. This therapy relies on efficient replication of virus in tumor cells in vivo with minimal or no replication in normal tissues. We recently described GLV-1h68 as a modified Vaccinia Virus (VACV) constr...
ORGANISM(S): Homo sapiens 
2012-03-24 | E-GEOD-28472 | biostudies-arrayexpress
UnknownA Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
Not available
S-EPMC11395026 | biostudies-literature
UnknownPembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Not available
S-EPMC11511690 | biostudies-literature
Sort   by:  
 Page size